Purpose. This study investigates the ef® cacy and toxicity of daily oral etoposide in chem oth erapy for non-heavily pretreated advan ced and m etastatic soft tissue sarcom a (STS). Subjects. Twenty-seven patients with progressive and m easurable disease were treated. M edian age was 53 years (range 20± 71 years) and perform ance statu s W H O 0 or 1. H istologies included m ainly leiom yosarcom a (8), m alignant ® brous histiocytom a (4), rhabd om yosarcom a (4), liposarcom a (2) and synovial sarcom a (2). Fifteen patients had received prior radiotherapy, of whom three included sites with haem atopo iesis. All patients had received prior chem otherapy, including adjuvant therapy (7) were done weekly. Dose reductions and a m axim um delay of 2 weeks was allowed depending on cell counts during treatm ent and at the start of a new 4-week treatm ent cycle. R esults. No objective respo nse was observed. Progressive disease was observed after two treatm ent cycles in 17/27 patients (68% ) and after th ree cycles in 22/27 patients (81% ). The other patients received three to ® ve cycles. Twenty-fou r patients went off study due to progressive disease. Grade 3 and 4 neutropenia was observed in eight and one patients, respectively. Throm bocytop enia grad e 3 was seen in tw o patients. N on-haem atological toxicity grade 3 (nausea, diarrhoea or alopecia) was observed in three patients, and grad e 4 (dyspnea, hypo tension or haem orrhage) in three patients. D iscussion. N o objective respo nse was obtained. O ral etopo side at a dose of 50 m g m 2 2 day 2 1 3 21 q 4 weeks is inactive in chem otherapy of pretreated ST S. Disease progression occurred within th ree cycles in the m ajority (81%) of patients. Toxicity of this regimen in non-h eavily pretreated patients is low.
Introduction
Etoposide (VP16/213) is a m ajor cytostatic agent w ith a broad antitum our spectrum. 1 In clinical practice, its schedule dependency has been established. 1, 2 Frequently used schedules are daily adm inistrations for 3 to 5 days or at days 1, 3 and 5. This schedule dependency prom pted clinicians to exam ine prolonged adm inistration schedules, in particular daily oral dosing, for 14± 21 days in 3-or 4-w eek cycles. This chronic adm inistration proved to be active in several m alignancies including solid tum ours such as breast cancer, gastric cancer, m esotheliom a and Kaposi sarcoma. 
H. J. Keizer et al. m as (STS).
6 N o objective responses were observed.
H alf of the patients received one cycle only, while the others received two cycles. Frequently, the daily dose or the num ber of treatment days had to be lim ited. Based on data of objective responses after prolonged adm inistration of oral etoposide in nonheavily pretreated patients, reported by som e m embers, the EO RT C-ST S G roup initiated a phase II study in pre-treated patients who had received one two-drug schedule or tw o single drugs only. (4), rhabdom yosarcom a (4), liposarcom a (2) and synovial sarcom a (2). F ifteen patients had received prior radiotherapy, of w hom three included sites with haem atopoiesis. All patients had received prior chem otherapy, including adjuvant therapy (7). T his chemotherapy consisted of one tw o-drug schedule (usually ifosfam ide and doxorubicin) or two single-drug regim ens. F urther in-and exclusion criteria were sim ilar to the standard phase II criteria of the EO RTC-ST S G roup. 
S ubjects and m ethods

Results
N o objective response w as obtained. After two cycles of treatment, progression was already present in 17/27 patients (68% ) and after three cycles in 22/27 patients (81%). T he ® ve rem aining patients had`no change' as their best response and received three to ® ve cycles of treatm ent. A total of 24 patients went off study due to tum our progression. Only one patient experienced grade 4 neutropenia (patient went off study), eight patients had grade 3 neutropenia, w ithout any fever. G rade 3 throm bocytopenia w as observed in two patients. O ne patient went off study after 2 weeks with a platelet count of 54 3 10 9 /l. Grade 4 non-m yelotoxicity occurred in three patients (one pulm onary embolism , one acute respiratory failure after the ® rst cycle and one gastrointestinal bleeding, without throm bocytopeniaÐ this patient went off study). T hese latter toxicities were de® nitely considered to be unrelated to the chem otherapy.
D iscussion
T he data presented show that in 27 patients w ho had been previously treated with two single-drugs regim ens or one two-drug combination, a regim en of 3 weeks oral etoposide (50 m g m 2 2 day 2 1 3 21, q 4 weeks) failed to achieve an objective response. M oreover, 22/27 patients (81%) already showed progressive disease after two or three courses of treatment. The toxicity of this regimen is low, which m ay be explained by the relatively low dose and the previously received chem otherapy. Yet, with a sim ilar regimen, Hainsw orth et al. 7 in refractory or resistant patients, reported 2/3 partial responses. Using higher dosages (3-w eekly intravenous 130 m g m 2 2 ) the EORT C-ST S G roup reported 1/26 patients with a partial response. 3 T he use of higher dosages in a daily oral schedule was reported by K am pe et al. 6 and resulted in severe m ucositis, gastrointestinal side-effects and m yelosuppression. N o response was seen in the 15 heavily pretreated patients (no further speci® cations were given). D iscontinuation of treatm ent and dose reductions were frequently needed in this latter study. There is hardly any data on etoposide as a single agent, in ® rst-line treatment for STS. T he Scandinavian Sarcom a Group used a com bination of etoposide and ifosfam ide (both as a continuous infusion) and found a 42% objective response rate. In second line studies the m ajority of reports, including our own, indicate that this drug does not have signi® cant ef® cacy. T he effect of etoposide as a ® rst-line single agent (oral or intravenous) in ST S has yet to be determined.
